Dr. Christopher J. Logothetis, MD
- Medicare services, 2024
- 407
- Medicare patients, 2024
- 224
- Part D claims, 2024
- 51
- Publications
- 412
- Clinical trials
- 13
- Practice address
- 1515 Holcombe Blvd, Houston, TX 77030
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Logothetis' professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Christopher J. Logothetis is a medical oncologist in Houston, Texas
Dr. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.
Dr. Logothetis' NPI, 1477654721, was assigned on September 26, 2006. Dr. Logothetis graduated from University of Athens in 1974. Dr. Logothetis holds Texas license F2328.
- NPI
- 1477654721NPI Registry (opens in a new tab)
- Medicare PAC ID
- 5496949018
- NPI enumeration date
- September 26, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 78
- Medical school graduation
- 1974
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Christopher J. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas
Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.
- The University of Texas MD Anderson Cancer Center1515 Holcombe Blvd, Houston, TX 77030
Source: Dmand AI Affiliation Data
Dr. Christopher J. Logothetis is affiliated with 1 site of care and 1 medical group
Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Christopher J. Logothetis' practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Logothetis practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| The University of Texas MD Anderson Cancer Center | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across The University of Texas System and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Christopher J. Logothetis is one of 484 medical oncologists in Texas
Medical oncology is Dr. Logothetis' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Logothetis is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Logothetis' licenses on file in 12 states: Texas, Florida, Michigan, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Alabama, Louisiana, Washington and Illinois.
Specialties and state licenses
- Medical oncology, TexasPrimary
- Florida license
- Michigan license
- Arizona license
- Georgia license
- Mississippi license
- Oklahoma license
- Tennessee license
- Alabama license
- Louisiana license
- Washington license
- Illinois license
Clinical focus
Dmand AI lists colorectal cancer, lymphoma and prostate cancer among the conditions Dr. Logothetis treats.
Medical oncologists near Dr. Logothetis
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Christopher J. Logothetis billed Medicare for 407 services in 2024
CMS data shows 407 Medicare services from Dr. Logothetis across 4 procedure codes in 2024, for 224 Medicare patients. Medicare paid $25,469 for them.
Dr. Logothetis' Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 4702024: 40713%
Where Dr. Logothetis' Medicare services took place, 2024
- In an office25061%
- In a facility15739%
Dr. Logothetis compared with the Texas median for medical oncologists, 2024
- Dr. Logothetis
- Texas median
- Medicare services
- 407vs 73645% below
- Medicare patients
- 224vs 20012% above
- Part D claims
- 12vs 33496% below
Medians across 448 medical oncologists in Texas with Dmand AI profiles that report each measure.
Dr. Logothetis' most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Logothetis?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Logothetis and other medical oncologists in Texas.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Christopher J. Logothetis treated 224 Medicare patients in 2024, average age 76
CMS counts 224 Medicare patients who saw Dr. Logothetis in 2024. The largest group is 75 to 84, with 97 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Logothetis' median patient age at 77, with 1% women.
Dr. Logothetis' Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Chronic conditions among Dr. Logothetis' Medicare patients, 2024
- Cancer75%
- High cholesterol75%
- High blood pressure74%
- Arthritis46%
- Ischemic heart disease40%
- Atrial fibrillation21%
- Chronic kidney disease19%
- Diabetes19%
Share of Medicare patients with each condition. A patient can have several.
Dr. Logothetis' patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 77
Patient panel by sex, all payers
- Women1%
- Men98%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Christopher J. Logothetis wrote 51 Medicare Part D claims in 2024
In 2024, Dr. Logothetis wrote 51 Medicare Part D claims for 18 patients. 67% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $138 in total drug cost. In 2023, CMS named 26 claims across 1 drug.
Dr. Logothetis' Part D claims by kind of drug, 2024
- Generic34 claims67%
- Brand-name17 claims33%
Dr. Logothetis' most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 262024: 1254%
Drugs named by CMS: 1 in 2024, 1 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Christopher J. Logothetis scored 84 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Logothetis for performance year 2024, reported as part of a group. Dr. Logothetis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Logothetis as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Logothetis' MIPS scores, performance year 2024
- 84of 100Final score
- 70.8of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 68of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Christopher J. Logothetis has 412 publications on record
Dmand AI links 412 papers to Dr. Logothetis, published from 2002 to 2025. 2016 was the busiest year, with 26. The most frequent topics are Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Bone Neoplasms. Dr. Logothetis has published most often in J Clin Oncol. Dr. Logothetis' most frequent co-authors are Eleni Efstathiou, MD, Jeri Kim, MD and Ana M. Aparicio.
Dr. Logothetis' papers by year, 2016 to 2025
Topics Dr. Logothetis writes about most
- Prostatic Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Bone Neoplasms
- Antineoplastic Agents
- Doxorubicin
- Disease Progression
- Neoplasm Metastasis
- Prostate-Specific Antigen
Dr. Logothetis' most frequent co-authors
Recent publications by Dr. Logothetis
Endocr Relat Cancer
See who Dr. Logothetis researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Logothetis works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Christopher J. Logothetis has worked on 13 clinical trials
Dmand AI links Dr. Logothetis to 13 clinical trials, 8 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Neoplasm Metastasis. M.D. Anderson Cancer Center sponsors the most, 9.
Clinical trials with Dr. Logothetis by phase
- 2Phase 1: 2 trials
- 2Phase 1/2: 2 trials
- 8Phase 2: 8 trials
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Logothetis' trials
- Prostatic Neoplasms
- Prostatic Diseases
- Neoplasm Metastasis
- Neoplastic Processes
Investigators on the most trials with Dr. Logothetis
Recent clinical trials with Dr. Logothetis
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide (opens in a new tab)
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Christopher J. Logothetis received $110,232 in industry payments from 2016 to 2025
CMS Open Payments shows 149 general payments to Dr. Logothetis from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Sanofi and Genzyme US Companies paid the most, $31,270. It also lists 9 research payments totaling $10,769 from 2016 to 2025.
General payments to Dr. Logothetis by program year, 2016 to 2025
General payments to Dr. Logothetis by kind, 2016 to 2025
- Consulting fees$88,68680%
- Travel and lodging$9,8799%
- Honoraria$6,7656%
- Food and beverage$4,6114%
- Education$2910%
Companies that paid Dr. Logothetis the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Christopher J. Logothetis has 4 awards and honors on record
Dmand AI lists 4 awards for Dr. Logothetis, most recently America's Top Doctors in 2014.
Awards and honors for Dr. Logothetis
- 2014
- America's Top Doctors
- 2013
- America's Top Doctors for Cancer
- Top Doctors:SE Texas
- Undated
- Super Doc
Source: Dmand AI Professional Profile Data
Dr. Christopher J. Logothetis graduated from University of Athens
Dr. Logothetis graduated from University of Athens in 1974.
- Medical school
- Board certified in internal medicine
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Christopher J. Logothetis accepts plans from 9 insurance carriers
Dr. Logothetis is in network with 9 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.
- Aetna
- Elevance
- United Healthcare
- Blue Cross Blue Shield of Michigan
- Aspirus Health Plan
- Blue Cross and Blue Shield of Kansas City
- Cigna
- CMS Medicare
- +1 more carriersWith a free account
Plan types Dr. Logothetis accepts, by number of carriers
- PPO6
- POS5
- HMO4
- Medicare4
- EPO3
Source: Dmand AI Insurance Network Data
Sources for Dr. Christopher J. Logothetis's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Awards and committee roles | Dmand AI Professional Profile Data |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Christopher J. Logothetis
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Christopher J. Logothetis' NPI number?
Dr. Christopher J. Logothetis' NPI number is 1477654721. It was assigned on September 26, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Christopher J. Logothetis?
Dr. Christopher J. Logothetis is a medical oncologist in Houston, Texas. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Christopher J. Logothetis practice?
Dr. Logothetis practices at 1515 Holcombe Blvd, Houston, TX 77030. Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.
What is Dr. Christopher J. Logothetis' medical license number?
Dr. Logothetis holds Texas license F2328, one of the licenses on file in 12 states.
Which states has Dr. Christopher J. Logothetis been licensed in?
Dmand AI has state licenses on file for Dr. Logothetis in Texas (1978 to 2026), Florida (since 2021), Michigan, Arizona (2023 to 2027), Georgia (2023 to 2026), Mississippi (2023 to 2026), Oklahoma (2020 to 2026), Tennessee (2023 to 2026), Alabama (2023 to 2025), Louisiana (2023 to 2025), Washington (2023 to 2025) and Illinois (1975 to 1982).
Which hospitals is Dr. Christopher J. Logothetis affiliated with?
Dr. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas.
What medical group is Dr. Christopher J. Logothetis part of?
Dr. Logothetis is linked to Physicians Referral Service.
Does Dr. Christopher J. Logothetis accept Medicare?
Yes. CMS data shows Dr. Logothetis billed Medicare for 407 services in 2024, and Dr. Logothetis accepts Medicare assignment.
Does Dr. Christopher J. Logothetis offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Logothetis as offering telehealth services.
What is Dr. Christopher J. Logothetis' MIPS score?
Dr. Logothetis' MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.
Show 10 more questionsShow fewer questions
How many Medicare patients does Dr. Christopher J. Logothetis see?
CMS counts 224 Medicare patients who saw Dr. Logothetis in 2024, with an average age of 76.
Is Dr. Christopher J. Logothetis board certified?
Yes. Dr. Logothetis is board certified in internal medicine by the American Board of Internal Medicine.
What services does Dr. Christopher J. Logothetis bill to Medicare?
In 2024, Dr. Logothetis' most billed Medicare services were office visit, established patient (99214), care management and other visits (99441) and office visit, established patient (99215).
Where did Dr. Christopher J. Logothetis go to medical school?
Dr. Logothetis graduated from University of Athens in 1974.
What drugs does Dr. Christopher J. Logothetis prescribe most?
In 2024 Medicare Part D data, Dr. Logothetis' most prescribed drugs by claims were Prednisone.
Has Dr. Christopher J. Logothetis received payments from drug or device companies?
CMS Open Payments shows $110,232 in general payments to Dr. Logothetis from 17 companies from 2016 to 2025. The largest total came from Sanofi and Genzyme US Companies.
How long has Dr. Christopher J. Logothetis been practicing?
Dr. Logothetis graduated from medical school in 1974, 52 years ago.
Does Dr. Christopher J. Logothetis do research?
Dmand AI links 412 publications to Dr. Logothetis, published from 2002 to 2025. Dr. Logothetis has worked on 13 clinical trials.
Who does Dr. Christopher J. Logothetis publish with?
Dr. Logothetis' most frequent co-authors are Eleni Efstathiou, MD (42 shared papers), Jeri Kim, MD (29 shared papers) and Ana M. Aparicio (24 shared papers).
What insurance does Dr. Christopher J. Logothetis accept?
Dr. Logothetis is in network with 9 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in Texas by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card